|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 21.42 USD | +4.03% |
|
+6.30% | -6.91% |
| 06-11 | HC Wainwright Initiates Damora Therapeutics at Buy With $45 Price Target | MT |
| 06-08 | TD Cowen Initiates Damora Therapeutics at Buy | MT |
| Market Cap | 1.32B 1.14B 1.05B 984M 1.85B 124B 1.87B 12.39B 4.82B 61.07B 4.95B 4.84B 211B | P/E 2026 * |
-11.2x | P/E 2027 * | -10.3x |
|---|---|---|---|---|---|
| Enterprise Value | 876M 755M 695M 654M 1.23B 82.64B 1.24B 8.23B 3.2B 40.56B 3.29B 3.22B 140B | EV / Sales 2026 * |
-
| EV / Sales 2027 * | - |
| Free-Float |
92.31% | Yield 2026 * |
-
| Yield 2027 * | - |
| 1 day | +4.03% | ||
| 1 week | +6.30% | ||
| Current month | -13.91% | ||
| 1 month | -12.93% | ||
| 3 months | -10.79% | ||
| 6 months | -18.65% | ||
| Current year | -6.91% |
| 1 week | 19.43 |  | 21.89 |
| 1 month | 18.59 | | 26.48 |
| Current year | 16.5 | | 33.99 |
| 1 year | 2.45 | | 38.33 |
| 3 years | 2.01 | | 92.5 |
| 5 years | 2.01 | | 144.75 |
| 10 years | 2.01 | | 449.75 |
| Manager | Title | Age | Since |
|---|---|---|---|
Jennifer Jarrett
CEO | Chief Executive Officer | 55 | 2026-03-29 |
Brian Burkavage
DFI | Director of Finance/CFO | - | 2026-04-30 |
Becker Hewes
CTO | Chief Tech/Sci/R&D Officer | 60 | 2026-01-04 |
| Director | Title | Age | Since |
|---|---|---|---|
Peter Harwin
CHM | Chairman | 40 | 2026-03-22 |
Christopher Cain
BRD | Director/Board Member | 42 | 2025-11-09 |
Julianne Bruno
BRD | Director/Board Member | 41 | 2025-11-09 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 04-30 | Other | Chief Financial Officer | 312,535 | 0.5077% | ||
| 03-29 | Free | Chief Executive Officer | 2,000,000 | 3.3200% | ||
| 03-22 | Free | Director | 37,313 | 0.0619% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +4.03% | +6.30% | +565.22% | -69.83% | 1.27B | |
| +3.23% | +2.25% | +65.02% | +113.87% | 54.54B | |
| +0.04% | +1.20% | +47.67% | +36.75% | 43.86B | |
| +3.04% | +7.05% | -12.15% | -18.06% | 22.63B | |
| +3.07% | +7.15% | -1.82% | +392.25% | 20.7B | |
| -0.53% | +0.54% | +16.19% | -37.07% | 15.84B | |
| +5.27% | +1.87% | +13.67% | -38.81% | 14.83B | |
| +0.65% | -0.27% | +26.80% | +174.70% | 13.1B | |
| -5.17% | +0.50% | +21.80% | - | 12.66B | |
| -0.27% | +6.06% | +78.78% | +104.79% | 11.56B | |
| Average | +1.34% | +1.45% | +82.12% | +73.18% | 21.1B | |
| Weighted average by Cap. | +1.54% | +1.96% | +38.09% | +89.66% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | - | - |
| Net income | -117M -101M -92.6M -87.16M -164M -11.02B -165M -1.1B -427M -5.41B -438M -429M -18.71B | -144M -125M -114M -108M -202M -13.62B -204M -1.36B -528M -6.69B -542M -530M -23.13B |
| Net Debt | -443M -382M -351M -331M -621M -41.79B -626M -4.16B -1.62B -20.51B -1.66B -1.63B -70.95B | -326M -282M -259M -244M -458M -30.8B -462M -3.07B -1.19B -15.12B -1.23B -1.2B -52.3B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-06-17 | 21.42 $ | +4.03% | 259,079 |
| 26-06-16 | 20.59 $ | +2.59% | 397,098 |
| 26-06-15 | 20.07 $ | -3.42% | 628,956 |
| 26-06-12 | 20.78 $ | -2.72% | 207,155 |
| 26-06-11 | 21.36 $ | +6.00% | 313,199 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- DMRA Stock
Select your edition
All financial news and data tailored to specific country editions
